BBH ETF Research - HOLDRS Biotech

HOLDRS Biotech (bbh)

Last Updated by Anonymous | Update This Page Now

►Summary | Add New ETF | Feedback

Short Term Rating Stock Ratings Help

Asset Allocation (% of Port)

US Stocks
Non-US Stocks

Geographic Allocation (% of Port)

North America
South America
Australia + Pacific Islands
Long Term Rating Stock Ratings Help


SWOT Statistics

Strengths + Opportunities = 87

Threats + Weaknesses = 53

When strengths & opportunities substantially exceed threats & weaknesses an investment in the bbh ETF has great long term potential.

ETF Description Update

HOLDRS Biotech (BBH) Description: BBH is an exchange trading fund (ETF), which is a security that tracks a basket of assets, but trades like a stock. BBH exchange trading fund (ETF) tracks the the general biotech indices; this etf has no specific benchmark. HOLDRS Biotech (BBH) falls under the Health & Biotech Equities category. BBH's dividend yield is roughly 0.03%, it has an expense ratio of 0.5%, and is in the equity ETF asset class. HOLDRS Biotech (BBH) focuses its investments in the Global/Multi-Region region of the world. BBH does not use leverage and BBH's performance is meant to match its benchmark. The BBH ETF belongs to the Health & Biotech sector. An investor can find BBH's top holdings, fundamental analysis, and fund ratings on the left side of the screen. The right side features BBH's technical analysis chart and long term fund potential. Long term and short term buy ratings indicate our highest possible valuation rating. Click here for additional information on Merrill Lynch HOLDRs ETF funds or see the ETF research & analysis home page to start.

Portfolio Strategy Update

Be the first to explain HOLDRS Biotech (BBH)'s strategy.

Performance Analysis Update